NASDAQ:ACRS - Aclaris Therapeutics Stock Price, Forecast & News

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics Inc (NASDAQ:ACRS) issued its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.80. The biotechnology company earned $0.98 million during the quarter, compared to analysts' expectations of $5.87 million. Aclaris Therapeutics had a negative return on equity of 83.22% and a negative net margin of 1,165.39%. View Aclaris Therapeutics' Earnings History.

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aclaris Therapeutics.

5 brokerages have issued 1-year target prices for Aclaris Therapeutics' shares. Their forecasts range from $5.00 to $13.00. On average, they anticipate Aclaris Therapeutics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 389.1% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.

News stories about ACRS stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Aclaris Therapeutics.

Aclaris Therapeutics saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 3,670,000 shares, a decline of 5.9% from the December 15th total of 3,900,000 shares. Based on an average trading volume of 951,100 shares, the short-interest ratio is currently 3.9 days. Approximately 11.0% of the company's shares are short sold. View Aclaris Therapeutics' Current Options Chain.

Some companies that are related to Aclaris Therapeutics include MannKind (MNKD), VBI Vaccines (VBIV), Kalvista Pharmaceuticals (KALV), BioXcel Therapeutics (BTAI), MediciNova (MNOV), Evofem Biosciences (EVFM), Geron (GERN), Osmotica Pharmaceuticals (OSMT), Avadel Pharmaceuticals (AVDL), IVERIC bio (ISEE), Wave Life Sciences (WVE), Neptune Wellness Solutions (NEPT), Sol Gel Technologies (SLGL), Kamada (KMDA) and BIOFRONTERA AG/ADR (BFRA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Nabriva Therapeutics (NBRV), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Exelixis (EXEL), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX) and Zynerba Pharmaceuticals (ZYNE).

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACRS stock can currently be purchased for approximately $1.84.

Aclaris Therapeutics has a market capitalization of $76.16 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]